in the case of a drug shortage, discontinuance, or interruption of the manufacture of a drug described in section 506C(a) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356c(a) ), including recommendations for notification to patients and physicians, pharmacists, and other practitioners authorized under applicable State law to prescribe or dispense drugs. (d) Effective date The amendments made by this section shall take effect on the date that is 180 days after the date of enactment of this Act. 3. GAO report on intra-agency coordination (a) In general Not later than 18 months after the date of the enactment of this Act, the Comptroller General of the United States shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report examining the Food and Drug Administration’s intra-agency coordination, communication, and decision making in assessing drug shortage risks, and taking corrective action. (b) Content The report shall include— (1) consideration of— (A) risks associated with violations of current good manufacturing practices